Significant Short Interest Growth in TEVA
According to the latest official FINRA short interest report for the settlement date of September 15, 2026, Teva Pharmaceutical Industries (TEVA) has experienced a substantial surge in bearish positioning. The data reveals that short interest in the stock has increased by more than tenfold compared to the previous reporting period. While FINRA data is inherently backward-looking—published approximately 18 days after the settlement date—this magnitude of change signals a significant shift in institutional sentiment toward the pharmaceutical giant. Investors should monitor whether this trend continues in the next reporting cycle or if the position is being unwound.
Signal data sourced from StockTitan. This post is an original analysis prepared by The Forensic Ledger from publicly available data. Not investment advice.
Not investment advice. This is original reporting and analysis prepared by The Forensic Ledger from publicly available data. Nothing here is a recommendation to buy, sell, or hold any security. Always consult the original source and a licensed professional. See our full disclaimer and source-citation policy.